Taiwanese Chinese translation and validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis 31 (QUALEFFO-31)  by Li, Wei-Chun et al.
Journal of the Formosan Medical Association (2013) 112, 621e629Available online at www.sciencedirect.com
journal homepage: www.jfma-onl ine.comORIGINAL ARTICLETaiwanese Chinese translation and
validation of the Quality of Life
Questionnaire of the European Foundation
for Osteoporosis 31 (QUALEFFO-31)Wei-Chun Li a, Yi-Chan Chen b, Rong-Sen Yang c, Ken N. Kuo d,
Ching-Yu Chen d, Jau-Yih Tsauo e,f,*aDepartment of Physical Therapy, Hungkuang University, Taichung, Taiwan
bTaipei Municipal Yang Ming Home for The Disabled, Taipei, Taiwan
cDepartment of Orthopaedic Surgery, National Taiwan University Hospital, College of Medicine,
National Taiwan University, Taipei, Taiwan
d Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan
e School and Graduate Institute of Physical Therapy, College of Medicine, National Taiwan University,
Taipei, Taiwan
f Physical Therapy Center, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan
Received 29 December 2011; received in revised form 5 September 2012; accepted 7 September 2012KEYWORDS
quality of life;
QUALEFFO-31;
Taiwanese Chinese
version;
translation;
validation* Corresponding author. School and
Road, Taipei 10055, Taiwan.
E-mail address: jytsauo@ntu.edu.t
0929-6646/$ - see front matter Copyr
http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Currently, Taiwanese Chinese version of a disease-specific health-related
quality of life questionnaire for osteoporosis is not available. The purpose of this study was to
translate and test the reliability and validity of the Taiwanese Chinese version of the Quality of
Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO-31).
Methods: The QUALEFFO-31 was translated from the original English to Taiwanese Chinese. In
this study, the translation procedure followed the guidelines described by Beaton et al. The in-
traclass correlation coefficient (ICC) was used to examine the test-retest reliability of the ques-
tionnaire. The internal consistency was assessed with Cronbach’s a; Pearson’s correlation was
used to assess convergent and discriminant validity; the Mann Whitney U test was used to
examine known group validity.
Results: The ICC for the test-retest reliability ranged from 0.77 to 0.91; Cronbach’s a for pain,
physical function, and mental function domains were 0.85, 0.74, and 0.79, respectively. For the
convergent and discriminant validity, the correlation coefficients of score of each item withInstitute of Physical Therapy, College of Medicine, National Taiwan University, Number 17, Xuzhou
w (J.-Y. Tsauo).
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622 W.-C. Li et al.score of pain domain and of other domains were 0.72e0.90 and 0.26e0.43, respectively; the
physical domain, 0.19e0.68 and 0.00e0.45; the mental domain, 0.53e0.71 and 0.11e0.38.
Conclusion: The Taiwanese Chinese version of the QUALEFFO-31 is reliable and valid. We
recommend this tool for evaluating participants with low bone mass in Taiwan. Further tests
should be conducted to confirm the use of this questionnaire in clinical practice.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Osteoporosis is the most prevalent metabolic bone disease
in older people. It causes significant morbidity, mortality
and expenditure in terms of health and social services.1,2 In
Taiwan, with fast growing aging population, the population
older than 65 years increased from 2% in 1950 to 8.6% in
20003 and to 10.7% in 2010.4 During the period 1999e2001,
the annual prevalence of osteoporosis in men and women
aged >50 years was 1.63% and 11.35%, respectively, in
Taiwan.5 Low bone mass is a common public health problem
in Taiwan. The Department of Health reported from
a survey of 2002 that the incidence of osteoporosis
increased significantly after menopause (w50 years of age)
for women in Taipei. In men, this increase occurs approxi-
mately 10 years later (at about age 65 years) compared
with women.6
Decreased health-related quality of life (HRQL) and
functional status have been described primarily in terms of
fracture-related pain and disability in women with severe
osteoporosis. Results of a previous study showed that
quality of life of osteoporotic women with fractures were
significantly worse in all domains compared with healthy
controls.2 Other studies reported that, even without frac-
tures, the quality of life of osteoporotic women was also
poor compared to other participants without osteoporosis,
total Quality of Life Questionnaire of the European Foun-
dation for Osteoporosis (QUALEFFO) scores were 39.5 and
25.6, respectively.7,8
Quality of life for participants with osteoporosis could be
measured with questionnaires. Several disease-specific
questionnaires with good validity and reliability are designed
for assessing quality of life of participants with osteopo-
rosis,1,9 which includeQUALEFFO,OsteoporosisQuality of Life
Questionnaire (OQLQ), Osteoporosis Assessment Question-
naire (OPAQ), Osteoporosis-Targeted Quality of Life Ques-
tionnaire (OPTQoL), Osteoporosis Functional Disability
Questionnaire (OFDQ), and Quality of Life Questionnaire in
Osteoporosis (QUALIOST).1,9,10 However, a TaiwaneseChinese
version of a disease- specific health-related quality of life
questionnaire has not been developed to date.
Recently, QUALEFFO was used in many large-scale
studies, such as the Multiple Outcomes of Raloxifene Eval-
uation (MORE) clinical trial.10 QUALEFFO was developed by
the European foundation for Osteoporosis in 1996 for
vertebral deformities. The questionnaire is used to assess
the burden of osteoporosis in QOL and the relevant changes
during treatment.11,12 Originally, the questionnaire
included 48 items, but was later condensed to 41 items
after validation and included five domains: pain, physical
function, social function, general health, and mentalfunction. QUALEFFO-41 has good test-retest reliability
(Kappa: 0.54e0.90) and internal consistency (Cronbach’s a:
0.72e0.92). The questionnaire can discriminate between
women with vertebral fractures and without fractures as
well as identify differences between groups by number and
location of vertebral fractures.10 It has been translated to
several languages and has also been reported to be valid
and reproducible.2 The other disease-specific question-
naires were not extensively used and validated in many
different countries.7
Recently, the European Foundation for Osteoporosis
developed a shorter and more practical instrument,13 the
QUALEFFO-31, which is a shorter version of the QUALEFFO-
41. It includes three domains: pain, physical function, and
mental function. Important advantages of the short version
are the reduced number of items and the decreased
amount of time (and burden) required by patients to
answer the questionnaire.13 However, there are few
versions available in another language.
Since there was no Taiwanese Chinese version available,
we selected QUALEFFO-31 as quality of life measuring
instrument. In 2010, the questionnaire was translated into
Chinese version and applied to local population of Hong
Kong.14 However, the cultural background and language
usage are different between Hong Kong and Taiwan, the
Hong Kong version is not entirely suitable for Taiwan pop-
ulation. Taiwan version is still needed for local researchers.
The purpose of this study was to translate and test the
reliability and validity of the Taiwanese Chinese version of
the Quality of Life Questionnaire of the European Founda-
tion for Osteoporosis (QUALEFFO-31).Materials and methods
This study was approved by the ethics committee of
National Taiwan University Hospital, No. 20071056R for
participants of test-retest reliability and 20090303OR for
participants of internal consistency and validity test.Translation
The translation procedure in this study followed the
guidelines described by Beaton et al.15
Step 1: forward translation
Two independent translators translated the questionnaire
(QUALEFFO-31) into Chinese. The translators each had
a version of the translation that they completed. Explana-
tory notes highlighted challenging phrases or uncertainties.
Translation and validation of QUALEFFO-31 623Poor word choices were identified and agreed upon after
comprehensive discussion between the two translators.
The two translators were bilingual and from different
backgrounds with Chinese as their mother language. One of
them (the second author) had a clinical background and
was aware of the concepts and contents of the QUALEFFO-
31. This translator provided considerations from a clinical
perspective. The other translator had no clinical back-
ground, and was not aware of the concepts of the ques-
tionnaire. This translator used common language in the
translation.
Step 2: synthesis of the translations
Reconciliation of these two forward versions was done
subsequently. An expert panel discussion was held on the
contention in wording. A written report was compiled to
document the synthesis process, address each issue, and
how to resolve these issues. After this process, the first
forward translation version of this questionnaire was
complete.
Step 3: back translation
A translation company translated this Chinese version of
the questionnaire back to English. The translator had no
medical background or knowledge of the QUALEFFO-31.
The translator was also blind to the original English version.
This validity checking process ensured that the translated
version reflected the same item content as the original
English version.
Step 4: expert committee
The goal of the committee was to achieve cross-cultural
equivalence. The committee comprised of one methodol-
ogist, one epidemiologist, and three health professionals.
Any discrepancies were reviewed and a consensus was
reached by the committee. The expert committee ensured
that equivalence was achieved between the English and
Chinese versions. During this process, the expert
committee was in contact with the developers of the
QUALEFFO-31 to verify any controversial or ambiguous
wording. Finally, the second Chinese version was finalized.
Step 5: test the pre-final version
Fourteen volunteers (11 females, three males; mean
age Z 70.8  8.4 years) from the hospital and the
community tested the pre-final Chinese version of the
questionnaire. The volunteers included healthy people and
people with a low bone mass; two of them had a bachelors
degree, and the others had a lower level of education (<12
years). All volunteers were asked to complete the ques-
tionnaire. They were also interviewed to explore their
perception and understanding of each item and the
response options in the questionnaire. This process was to
ensure that the adapted version was still retaining its
equivalence when applied in practice. After this process,
the final Chinese version was developed.
Step 6: submission of documentation to the developers to
appraise the adaptation process
All the reports and forms were submitted to the Interna-
tional Osteoporosis Foundation (IOF) to ensure that
a reasonable translation was achieved. Hereafter, thisTaiwanese Chinese version’s psychometric properties were
examined.Assessment of the translated QUALEFFO-31
Participants
Participants older than 50 years were recruited from
outpatient orthopedic clinics and from the community. The
inclusion criteria were: (1) participants who had dual-
energy X ray absorptiometry (DXA) report. In community,
the participants were screened with “1-minute osteoporosis
risk test,” it was recommended by The Taiwanese Osteo-
porosis Association to find the risk of osteoporosis. If
participants with more than one risk factor would be
referred to orthopedic clinics for DXA assessment, and the
cost of examination was provided by our grants; (2) partic-
ipants who were willing to participate; and (3) participants
who could understand and answer the questions asked in
this questionnaire. The following participants were
excluded: (1) participants with any severe neuromuscular
diseases (e.g., stroke, spinal cord injury, peripheral nerve
injury) and other diseases that might influence quality of
life; (2) participants with impaired cognition unable to
understand the questionnaire and verbal instructions.
Depending on the participant’s situation, convenient
modesofadministrationwereusedtocollectdata in this study
including telephone, self-report or face-to-face interview.
Instruments
QUALEFFO-31 consists of three domains, including: pain
(four items); physical function (18 items); and mental
function (nine items). Each item has four or five possible
responses.13 Domain scores were calculated by the sum of
the scores of questions included in the domain and trans-
formed to a scale of 0 to 100. A total QUALEFFO score was
calculated by the sum of the scores of all questions and
submitting the score to a linear transformation to a scale of
0 to 100. The lowest score represented the best QOL and
the highest score represented the worst QOL.2
The European Quality of Life Scale (EQ-5D) is a generic
questionnaire that was also used to measure the QOL of
participants. It is a simple and easy to use questionnaire;
its reliability and validity was evaluated. This question-
naire divides health status into five dimensions: (1)
mobility, (2) self care, (3) usual activities, (4) pain/
discomfort, and (5) anxiety/depression. Each dimension is
divided into three degrees of severity: no problem, some
problems and major problems, with an allocated value of
1, 2, and 3, respectively. The participants were asked to
mark the degree of severity which best described their
actual health status. The five health dimensions summa-
rize health status into 243 (35) possible health states. The
values for these health states, estimated by time trade
off (TTO) utility values, have been developed previ-
ously.16,17 The Taiwanese Chinese version of EQ-5D
was previously tested and validated in the Taiwanese
population. 18
Reliability test
Two types of reliability were examined, including test-
retest reliability and internal consistency.
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QUALEFFO-31 was repeated for analysis with a 2-week
interval in 41 participants by same assessor. All of the
participants were postmenopausal women with low bone
mass.
Internal consistency was determined with Cronbach’s
alpha (a value). This version of the questionnaire was
completed by 200 participants. A value 0.70 is considered
as acceptable for group comparisons.19
Validity test
The convergent, discriminant, known group, and construct
validity were examined. In addition, the correlation
between QUALEFFO-31 and EQ-5D was assessed. These two
questionnaires were completed by 200 participants.Statistical analysis
The SPSS statistical package version 11.0 for Windows (SPSS
Inc., Chicago, IL, USA) was used to analyze the data.
The test-retest reliability between two repeated
measures of the same subject was examined using intra-
class correlation coefficient (ICC). The internal consistency
was assessed with Cronbach’s a.
Pearson’s correlation was used to assess convergent and
discriminant validity. If the correlation coefficient between
the score for each item and its own total domain score was
larger than 0.40, it had adequate convergent validity; when
the correlation coefficient of the score for each item with
its own domain score was higher than the correlation
coefficient of total scores of other domains, it had
adequate discriminant validity.2,20 The convergent and
discriminant validity ratio were also calculated,13,20 the
convergent validity ratio is the number of items fitted the
criteria of convergent validity in this domain divided by
number of items in this domain; the discriminant validity
ratio is the number of items fitted the criteria of discrimi-
nant validity in this domain divided by number of items in
this domain.
Using EQ-5D as the gold standard, Spearman’s rank
correlation between the similar domains in QUALEFFO-31
and EQ-5D was performed. Pearson’s correlation was also
performed between QUALEFFO-31 and utility values of EQ-
5D.
In all statistical analyses, a correlation coefficient of 0 to
0.25 was interpreted as “no or very poor” correlation;
>0.25 to 0.50 was regarded as “poor-moderate” correla-
tion; >0.50 to 0.75 was regarded as “good” correlation and
>0.75 to 1.00 was regarded as “very good” correlation.2
A p value less than 0.05 was considered to be statisti-
cally significant. In addition, the participants were
regrouped to normal and low bone mass based on the scores
of bone mineral density to examine the known group val-
idity. Participants with normal or low bone mass (osteope-
nia or osteoporosis) were diagnosed according to the World
Health Organization published criteria based on bone
mineral density (BMD) measurement at the spine or hip with
DXA (low bone mass is T score <1, normal is T score 
1). The normality of the variables’ distribution was
checked with Kolmogorov-Smirnov one sample test, and the
data did not match the assumption of normal distribution,then the Mann Whitney U test was used to compare the
total and domain scores of QUALEFFO-31 between the two
groups.The construct validity was assessed by factor
analysis, and the procedure was described as
follows
Factor analysis of the QUALEFFO-31 using the LISREL 8.80
software (SSI Inc., Chicago, IL, USA) was conducted. The
analysis procedure was described as follows.
We first conducted exploratory factor analysis (EFA) of
the sample covariance matrix using the principal factor
estimation method and the oblique promax rotation to
explore the factor structure in the 200 participants. Then,
we took the final three-factor model from EFA as the initial
factor model for confirmatory factor analysis (CFA) of the
same sample covariance matrix to verify and refine the
measurement structure. To assure the quality of analysis
results, basic model-fitting techniques were applied in CFA.
First, with the aid of substantive knowledge and insight,
stepwise variable selection was performed by iterating the
following two actions: (1) using Wald’s t test to drop an
insignificant structural parameter and (2) using the modi-
fication index (MI) to add an additional meaningful struc-
tural parameter. Next, in addition to chi-square goodness-
of-fit test, the Goodness-of-Fit Index (GFI), adjusted GFI,
root mean square error of approximation (RMSEA), and
comparative fit index (CFI) were particularly examined for
assessing the adequacy of fit. The usual cut-off values for
well-fitted factor models in CFA are GFI and adjusted
GFI > 0.95, RMSEA < 0.06 (or 0.05), and CFI > 0.95. Finally,
model diagnosis was conducted by examining the estimated
factor loadings, the estimated correlations between latent
variables and between measurement errors, and the stan-
dardized residual variance-covariance matrix to detect
model problems and identify poorly fitted relationships.Results
Participant characteristics
The demographic data and the scores for each question-
naire are reported in Table 1. The mean age, weight, and
height of participants included in the test-retest reliability
was 70.8  8.4 years, 52.8  8.1 kg, and 154.1  5.3 cm,
respectively; and those for internal consistency and validity
was 71.1  5.1 years, 61.0  11.0 kg, and 151.8  25.1 cm,
respectively. The majority of participants were women.Reliability test
The ICC for the test-retest reliability ranged from 0.77
(pain domain) to 0.91 (physical domain; Table 2).
All Cronbach’s a of item-total correlation (omitted that
item) for internal consistency in three domains of multiple-
item scales were greater than the 0.70, the minimal
psychometric standard recommended for reliability (ranged
from 0.70 to 0.86). Cronbach’s a of pain domain, physical
Table 1 Demographic data and results of questionnaires.
Reliability test
(N Z 41)
Internal
consistency
and validity
(N Z 200)
Age (yr) 70.8  8.4 71.1  5.1
Weight (kg) 52.8  8.1 61.0  11.0
Height (cm) 154.1  5.3 151.8  25.1
Sex (n)
Female 41 129
Male 0 71
Severity (n)
Osteoporosis 25 97
Osteopenia 16 65
Normal 0 38
QUALEFFO-31 Test Retest
Pain domain 19.4  20.0 21.5  22.5 19.2  25.0
Physical domain 9.1  8.3 10.3  9.8 12.0  9.3
Psychological
domain
29.2  14.9 31.5  13.2 26.2  16.6
Total score 16.2  9.3 17.9  10.4 17.1  10.4
EQ-5D
Taiwan utility 0.91  0.10 0.90  0.12 0.94  0.09
UK utility 0.81  0.13 0.79  0.19 0.84  0.13
EQ-5D Z European Quality of Life Scale; QUALEFFO-
31 Z Quality of Life Questionnaire of the European Foundation
for Osteoporosis 31.
Table 3 Convergent and discriminant validity ratios of
each domain of the Taiwan Chinese version of the QUAL-
EFFO-31.
Domain Convergent
validity ratio (%)
Discriminant
validity ratio (%)
Pain 100 100
Physical function 72 100
Mental function 100 100
QUALEFFO-31 Z Quality of Life Questionnaire of the European
Foundation for Osteoporosis 31.
Translation and validation of QUALEFFO-31 625function, and mental function domain was 0.85, 0.74, and
0.79, respectively.Validity test
For convergent validity, the correlation coefficient of score
of each item in pain, physical and mental domain with its
own domain score was 0.72e0.90, 0.19e0.68, and
0.53e0.71, respectively. For the discriminant validity, the
correlation coefficient of score of each item in pain,
physical, and mental domain with total scores of other
domains was 0.26e0.43, 0.00e0.45, and 0.11e0.38,
respectively. Each correlation coefficient between score of
each item with total score of related domain was higherTable 2 Intraclass correlation coefficient of reliability
test (N Z 41).
ICC
QUALEFFO-31
Pain domain 0.77*
Physical domain 0.91*
Mental domain 0.83*
Total score 0.87*
*p < 0.05.
ICC Z intraclass correlation coefficient; QUALEFFO-
31 Z Quality of Life Questionnaire of the European Foundation
for Osteoporosis 31.than that with total score of unrelated domain. The ratio of
convergent and discriminant validity is reported in Table 3.
Spearman’s and Pearson’s correlation coefficients
(r values) for the validity of QUALEFFO-31 with the EQ-5D
are included in Table 4. The correlation coefficient of the
total score of QUALEFFO-31 with the EQ-5D utility of Taiwan
and United Kingdom were 0.60 and 0.56, respectively
(p < 0.05).
The Mann Whitney U test was used to analyze the known
group validity, and the result showed that the mental
domain of QUALEFFO-31 had significant difference between
low bone mass and normal group (p < 0.05; Table 5).
EFA and CFA were used to assess construct validity
Our EFA of the covariance matrix with the oblique promax
rotation yielded a three-factor structure of the QUALEFFO-
31 (31 items) as listed in Table 6. The factor 1 (pain, items
1e4; physical, items 10e13 and 16e18), factor 2 (physical,
items 4e9), and factor 3 (mental, items 1e9) were slightly
different from the original structure of three domains
(pain, physical, and mental). The estimated correlations
between our three factors were r1,2 Z 0.272,
r2,3 Z 0.167, and r1,3 Z 0.513, where the subscript
indexed the three latent variables.
We performed CFA to verify the three-factor structure
obtained from EFA. Yet, we found two special problems in
our instrument and data. First, the Pain scale (four items)
actually included two types of items: (1) items 1 and 2
together measured frequency, but (2) items 3 and 4
measured intensity (or severity) and impact respectively.
The combination of these two different types of items in
CFA would be problematic; thus, we decided to consider
only items 3 and 4 in our CFA. Second, the frequency
distributions of some items were very skewed with small
variances. In particular, the responses of pain, item 4, and
physical, items 1-7, 9, 12, and 15, concentrated on the
answer of ‘1,’ indicating strong floor effects. Hence, after
dropping pain, items 1e2, 4, physical, items 1e7, 9, 12, and
15, we specified a two-factor measurement model in our
CFA, and then went through the above-mentioned model-
fitting process. As shown in Fig. 1, the final CFA model
(factor 1: pain, item 3, physical, items 8, 10, 11, 13, 17, 18,
and factor 2: mental, items 1, 5e9) showed an adequate fit
(Chi-square goodness-of-fit test statisticZ 87.80, dfZ 60,
p value Z 0.01114 > 0.01, RMSEA Z 0.048 < 0.05, and
CFI Z 0.956 > 0.95).
Table 4 Validity: using EQ-5D as gold standard, the correlations between QUALEFFO-31 and EQ-5D.
r value Mobilitya Self
carea
Usual
activitiesa
Pain/
discomforta
Anxiety/
depressiona
EQ-5D Taiwan
utilityb
EQ- 5D UK
utilityb
QUALEFFO-31
Pain 0.09 0.10 0.11 0.45* 0.18* 0.42* 0.43*
Physical function 0.31* 0.11 0.19* 0.31* 0.20* 0.44* 0.38*
Mental function 0.09 0.06 0.16* 0.41* 0.42* 0.53* 0.50*
Total scores 0.24* 0.11 0.20* 0.48* 0.34* 0.60* 0.56*
*p < 0.05.
EQ-5DZ European Quality of Life Scale; QUALEFFO-31Z Quality of Life Questionnaire of the European Foundation for Osteoporosis 31.
a Speaman’s correlation between domain scores of QUALEFFO-31 and those of EQ-5D.
b Pearson’s correlation coefficient between domain scores of QUALEFFO-31 and utility value of EQ-5D.
Table 6 Promax-rotated factor loadings.
Items Factor 1 Factor 2 Factor 3
Pain 1 0.635 0.157 0.129
Pain 2 0.678 0.125 0.054
Pain 3 0.639 0.179 0.142
Pain 4 0.646 0.164 0.076
Physical 1 0.179 0.027 0.099
Physical 2 0.230 0.052 0.040
Physical 3 0.127 0.191 0.185
Physical 4 0.040 0.825 0.112
Physical 5 0.045 0.748 0.050
Physical 6 0.107 0.860 0.031
Physical 7 0.040 0.826 0.044
Physical 8 0.248 0.380 0.119
Physical 9 0.140 0.436 0.192
Physical 10 0.637 0.115 0.016
Physical 11 0.554 0.167 0.066
Physical 12 0.487 0.147 0.099
Physical 13 0.627 0.170 0.145
Physical 14 0.029 0.137 0.026
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This is the first Taiwanese Chinese version of a disease-
specific questionnaire for participants with low bone mass.
After translation and cross-cultural adaptation, even
participants with a lower level of education were able to
understand the meaning of the questionnaire. Moreover,
the psychometric measures showed this questionnaire is
reliable and valid.
Because of different cultural backgrounds, during the
translation, slight modifications were made, instead of
translating directly from the original English. For example,
Questions 8 and 13 relating to physical function domain
state, “Can you lift a heavy object of 20 pounds (e.g.,
a crate of 12 bottles of milk or a 1-year old child) and carry
it for at least 10 yards?” and “Can you walk 100 yards?,”
respectively. The units “pound” and “yard” are rarely used
in Taiwan; therefore, we changed the units of weight and
length to metric system as “kilogram” and “meter,”
respectively. In question 16 relating to physical function
domain, “Can you do your gardening?” Gardening is not
a popular physical activity in Taiwan. Originally, we plan-
ned to revise this activity to a common activity in Taiwan
such as, “Can you take care of plants?”; however, the
author suggested to retain the original wording, and we,
therefore, used the direct translation for this item.
For the reliability of this study, the ICC ranged from 0.77
to 0.91. This result indicated satisfactory test-retest reli-
ability. The Cronbach’s a for internal consistency of item-
total correlation and domains was greater than 0.70, which
indicated that the translated version had adequate
reliability and corresponded with previous findings. InTable 5 Scores (mean  SD) of each domain of Quality of
Life Questionnaire of the European Foundation for Osteo-
porosis 31 with different bone mass.
Low bone mass
(N Z 162)
Normal
(N Z 38)
Pain domain 19.4  24.7 18.0  26.3
Physical domain 12.6  9.8 9.6  6.3
Mental domain 27.4  16.8 21.1  14.8*
Total score 17.8  10.7 14.0  8.5
*p < 0.05.Malaysian version, the study on internal consistency of
QUALEFFO-41 was generally good; the Cronbach’s a ranging
between 0.67 and 0.93 for each domain.21 Similar results
were achieved in other studies in Europe (0.72e0.92),22 UK
(0.65e0.90),23 and Turkey (0.70e0.97).2 In 2006, the study
which developed QUALEFFO-31 reported that the Cron-
bach’s a for internal consistency of domains was 0.72 for
pain domain (smaller than this study), 0.93 for physical
function domain (larger than this study), and 0.79 for
mental function domain (same as this study).13Physical 15 0.034 0.285 0.055
Physical 16 0.346 0.170 0.122
Physical 17 0.396 0.076 0.071
Physical 18 0.476 0.021 0.243
Mental 1 0.177 0.171 0.408
Mental 2 0.152 0.114 0.500
Mental 3 0.058 0.087 0.742
Mental 4 0.151 0.077 0.735
Mental 5 0.160 0.063 0.480
Mental 6 0.201 0.003 0.334
Mental 7 0.091 0.023 0.518
Mental 8 0.065 0.019 0.394
Mental 9 0.019 0.009 0.660
Figure 1 Confirmatory factor analysis. PHY 8, 10, 11,13 Z physical 8, 10, 11, 13. PHY 17 RE, 18 RE Z physical 17, 18. PSY 1, 5,
7 Z mental 1, 5, 7. PSY 6 RE, 8RE, 9 RE Z mental 6, 8, 9.
Translation and validation of QUALEFFO-31 627For the validity of this study, most items had adequate
convergent validity (the correlation coefficient between
the score for each item and its own total domain score was
>0.40). However, coefficients for some items (physical
domain, items: 1e3, 14e15) were lower than 0.4. These
five items are related with severe osteoporosis or defor-
mation, however, the subjects in this study are relatively
healthy; it may be the reason for this result. The conver-
gent validity ratio ranged from 72% (physical function
domain) to 100% (pain and mental function domains); and
the discriminant validity ratio was 100% for the three
domains. In 1999, the study of Lips and coworkers22 on
QUALEFFO-41 reported the same ratios for convergent
validity (78%e100%) and discriminant validity (72%e100%).
Kocyigit et al2 showed that the ratio of convergent and
discriminant validity for QUALEFFO-41 ranged from 89% to
100%. In van Schoor’s13 study on QUALEFFO-31 showed that
the convergent validity ratio was 100% for pain domain, 94%
for physical function, and 89% for mental function domain.
For the discriminant validity ratio, each item with its
domain score was higher compared with the other domain
scores (100%).13 Our results were similar comparing with
previous studies mentioned above, indicating that theconvergent and discriminant validities of this questionnaire
were compatible.
Good correlation was reported between the total score
of the translated version and EQ-5D utility, and moderate
correlation was noticed between similar domains. This
indicates that the validity of the questionnaire is accept-
able. The moderate correlation (r Z 0.41) between the
mental domain of QUALEFFO-31 and pain/discomfort
domain of EQ-5D in our study indicated that pain may affect
psychological function. Oleksik’s study24 in postmenopausal
women with low BMD reported that the correlation of the
total score of QUALEFFO-41 and utility of EQ-5D was e0.75;
the correlation between the pain domain of QUALEFFO-41
and pain/discomfort was 0.57; the correlation between
the physical function domain of QUALEFFO-41 and mobility
of EQ-5D was 0.59; and the correlation between mental
function of QUALEFFO-41 and anxiety/depression domain
of EQ-5D was 0.50. The correlations in Oleksik’s study24
were higher than the current study. However, it was
hypothesized that rating scales would correlate substan-
tially with each other with Pearson’s correlation >0.40.25
From the results of our study, this Taiwanese Chinese
versionofQUALEFFO-31wasable todifferentiate the subjects
628 W.-C. Li et al.with different bone mineral statuses in mental domain, but
not in other domains. Small sample size of normal participants
may be a possible reason for this result. It will be necessary to
include more participants in further studies. In addition, we
did not monitor the influence of medication in the low bone
mass group. The scores of their pain and physical domain of
quality of lifemight not be the sameas untreated participants
with low bone mass. This might be the other reason of not
significant difference between these two groups.
There were limitations in this study. Firstly, our partici-
pants were a convenient sample and not randomly selected.
The participants were recruited from hospital and the
community. The generalizability of the quality of life scores
was limited. Secondly, telephone administration, self-
administration or interview administration was performed
in this study. Different modes of administration might cause
random error. The QUALEFFO was developed as a self-
administered instrument, which might suit the question-
naire best. There might be an advantage in combining
different types of administration to evaluate participants in
different situations (such as age, level of education, vision
problems). Thirdly, the result of known group validity test
may be affected by case number difference in low bonemass
group and normal participant group. Fourthly, only post-
menopausal women participated the test-retest reliability
study, generalization of this result might be limited.
In summary, bone health and quality of life were influ-
enced in participants with osteoporosis; the impact of QOL
deterioration is often neglected. The development of
Taiwanese Chinese version QOL questionnaire is necessary
for clinical research and assessment. We can know the well
being of patients, and we can find patients problems in
addition to physical function. The Taiwanese Chinese
version of the QUALEFFO-31 is reliable and valid. This
version of the questionnaire includes fewer items; it is
more friendly and spending less time in answering as
compared with QUALEFFO-41 and others. We therefore
recommend this tool in evaluating Taiwanese participants
with low bone mass. However, most participants in this
study were relatively healthy with osteoporosis; they can
live independently in community, the generalization to all
osteoporosis patients should be cautious. In addition, few
studies have been done on QUALEFFO-31 and additional
testing should be undertaken to confirm the potential and
clinical practice of this questionnaire in the future.
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